
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moroctocog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moroctocog Alfa is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : Moroctocog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moroctocog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
Details : Moroctocog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 18, 2012
Lead Product(s) : Moroctocog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All